Enclomiphene alternatives: TRT, clomiphene, hCG and SERMs compared

Last updated 2026-07-30

What are the real alternatives to enclomiphene?

If you're looking at enclomiphene because you want your testosterone up without shutting down sperm production, you've got four broad categories to actually choose from: injectable or topical testosterone (TRT), clomiphene citrate, human chorionic gonadotropin (hCG), and other selective estrogen receptor modulators (SERMs) like tamoxifen or raloxifene. There's also the "do nothing yet, just tighten up sleep and body composition" path, which is a legitimate first move for a lot of men with borderline-low labs. None of these are interchangeable. TRT reliably raises testosterone but shuts down the hypothalamic-pituitary-testicular (HPT) axis, dropping sperm counts, often to zero, within months ^[1]. Clomiphene and enclomiphene work upstream, at the hypothalamus and pituitary, so they raise your own testosterone while leaving the sperm-production machinery running. hCG works even further downstream, mimicking LH directly at the testes. Each has a different evidence base, a different FDA status, and a different cost. The honest starting point: enclomiphene itself is not FDA-approved. The drug that was supposed to bring it to market, Androxal, went through Phase 3 trials and was never approved by the FDA ^[2]. What's sold today as "enclomiphene" comes from compounding pharmacies under a physician's prescription, which is legal but means it isn't manufactured under the same quality and efficacy review as an approved drug. That single fact should shape how you think about every alternative on this list, because most of them share the same off-label or compounded status.

Is testosterone therapy (TRT) a better option than enclomiphene?

TRT is better at raising testosterone predictably and it's FDA-approved in forms like testosterone cypionate, gels, and pellets. It is not better for fertility. Exogenous testosterone suppresses the hypothalamic-pituitary-testicular axis, and most men on TRT see a sharp drop in sperm concentration, with azoospermia (zero sperm) common within 3 to 6 months of starting ^[1][3]. A widely cited male contraception study using injectable testosterone (with or without progestin) found that testosterone-based regimens suppressed sperm to near-zero levels in the vast majority of participants, which is exactly the mechanism working against you if you want kids later ^[3]. TRT also shrinks testicular volume, because the testes stop getting the LH signal they need to keep the local machinery running. If fertility isn't a near-term concern and you want the most established, FDA-approved way to raise testosterone, TRT is a defensible choice. If you're actively trying to conceive, or think you might be in the next couple of years, TRT alone is close to the opposite of what you want. Many clinics pair TRT with hCG to blunt testicular shrinkage, but that adds cost and complexity rather than solving the underlying tradeoff. For a side-by-side on how enclomiphene stacks up against this path, see enclomiphene pros and cons.

How does clomiphene citrate compare to enclomiphene?

Clomiphene citrate is the parent drug, and it's actually a mixture of two isomers: enclomiphene (the trans-isomer) and zuclomiphene (the cis-isomer). Enclomiphene is the isomer that does most of the work at the hypothalamus, blocking estrogen feedback and driving up LH and FSH, which in turn raises testosterone and supports sperm production ^[4]. Zuclomiphene has a much longer half-life, roughly 30 days versus enclomiphene's roughly 10 hours, and it's the component more associated with estrogenic side effects like mood changes and visual disturbances, though the data separating the two isomers' side effect profiles in men is still limited ^[4][5]. Clomiphene is FDA-approved, but only for female infertility; its use in men to raise testosterone is off-label, same as enclomiphene. In practice, clomiphene is cheaper and easier to get because it's a generic, approved drug that any pharmacy can dispense, while enclomiphene requires a compounding pharmacy. Some men tolerate clomiphene fine. Others report more moodiness or visual side effects, which is the theoretical rationale for isolating enclomiphene in the first place. A 2013 pharmacokinetic and endocrine study of enclomiphene in men found it increased LH, FSH, and total testosterone while, unlike TRT, not suppressing sperm parameters over the treatment period ^[6]. That's the core evidence enclomiphene advocates lean on, but it's a small, short-duration study, not a large FDA-reviewed trial, and you should treat the fertility-preservation claim as "consistent with the mechanism and early data," not "proven long-term outcome."

Does hCG work as an alternative to enclomiphene?

hCG (human chorionic gonadotropin) mimics luteinizing hormone (LH) and acts directly on the testes, telling them to produce testosterone and support spermatogenesis, without needing the hypothalamus or pituitary to cooperate. It's FDA-approved for certain conditions including hypogonadotropic hypogonadism, and it's commonly used off-label alongside TRT to prevent testicular atrophy ^[7]. The practical difference from enclomiphene: hCG is injectable, usually two to three times a week, and it's meaningfully more expensive out of pocket, often several hundred dollars a month depending on dose and pharmacy. It also doesn't fix an underlying pituitary signaling problem; it bypasses it. If your low testosterone is driven by low LH from the pituitary (secondary hypogonadism), hCG can work well. If the testes themselves are the problem (primary hypogonadism), hCG won't help much, and neither will enclomiphene, because both depend on functioning testicular tissue. Some protocols combine a SERM with low-dose hCG, especially for men prioritizing fertility, but that's more complexity, more cost, and more injections than most enclomiphene users are looking for. If needles are a dealbreaker, that alone rules out hCG.

What about other SERMs like tamoxifen or raloxifene?

Tamoxifen and raloxifene are both SERMs, same drug class as clomiphene and enclomiphene, and both are FDA-approved, but for breast cancer treatment and prevention, not for male hypogonadism ^[8][9]. Their use to raise testosterone is off-label and the male-specific evidence is thinner than what exists for clomiphene and enclomiphene. Tamoxifen has been studied in small trials for male infertility and gynecomastia, and it does raise LH and testosterone through the same estrogen-receptor-blocking mechanism at the hypothalamus ^[8]. Raloxifene has some data in adolescent gynecomastia and a smaller amount in adult male hypogonadism research contexts, but it's not a mainstream TRT-alternative in clinical practice ^[9]. Neither has anywhere near the volume of "men using this specifically to raise T while preserving fertility" data that clomiphene and enclomiphene have accumulated over the past two decades, most of it observational and small-sample rather than large randomized trials. If a clinic pitches you tamoxifen or raloxifene as a testosterone booster, ask directly what data supports the dose and duration they're recommending, because you're now two steps further from anything the FDA has reviewed for this purpose.

Does anastrozole or another aromatase inhibitor work instead of enclomiphene?

Aromatase inhibitors (AIs) like anastrozole work through a completely different mechanism: they block the conversion of testosterone to estrogen, rather than blocking estrogen's feedback signal at the hypothalamus. Lowering estrogen can indirectly raise LH and testosterone somewhat, but AIs are not FDA-approved for male hypogonadism and the evidence for meaningful, sustained testosterone gains in men with normal-to-low testosterone is weak and mixed ^[10]. There's also a real downside risk: driving estrogen too low in men is linked to worse lipid profiles and reduced bone mineral density in some studies, since men need a baseline level of estrogen for bone and cardiovascular health, more than for reproductive function ^[10]. This isn't a "stronger enclomiphene," it's a different tool with a different risk profile, and most endocrinologists don't reach for it as a first-line testosterone strategy. AIs sometimes show up in bodybuilding-adjacent protocols to manage estrogen while on other compounds, which is a different goal entirely from raising baseline testosterone in a hypogonadal man who wants to preserve fertility.

Which alternative preserves fertility best?

Based on mechanism and the available human data, clomiphene and enclomiphene have the best-established track record for raising testosterone while keeping spermatogenesis intact, because they work upstream of the testes and keep the LH/FSH signal running ^[4][6]. hCG can also support fertility, particularly when combined with a SERM, but it doesn't address a pituitary-level problem the way a SERM does. TRT is the clear loser on this specific question. If fertility preservation is your priority, TRT alone is the option to avoid, and the male contraceptive trial data essentially proves the point in reverse: exogenous testosterone is potent enough at suppressing sperm that it's been studied as a contraceptive ^[3]. Here's a comparison of where each option lands: | Option | FDA-approved for low T in men? | Fertility effect | Typical route | Rough monthly cost |

Is enclomiphene FDA-approved, and does that matter for choosing an alternative?

No. Enclomiphene is not FDA-approved as a standalone drug. Repros Therapeutics developed it under the brand name Androxal and ran Phase 3 trials for secondary hypogonadism, but the program never secured FDA approval and was discontinued ^[2]. What's sold today comes from compounding pharmacies, which operate under different rules than manufacturers of approved drugs. Compounded drugs are prepared by a licensed pharmacy for an individual patient's prescription and are regulated under section 503A of the Federal Food, Drug, and Cosmetic Act, which explicitly exempts them from the FDA's standard new-drug approval, adequate directions for use, and manufacturing requirements that apply to approved products ^[11]. The FDA's own guidance states that compounded drugs "are not FDA-approved," meaning they haven't been evaluated by the FDA for safety, effectiveness, or quality before reaching patients ^[12]. This matters for every alternative on this list, more than enclomiphene. Clomiphene and tamoxifen are FDA-approved drugs, just not for this use in men, so at least the manufacturing and quality bar is the approved-drug standard, even though your doctor is prescribing off-label. Enclomiphene has neither an approval for this use nor an approval for any use; it exists only through compounding. That's not automatically disqualifying, plenty of compounded medications are safe and effective, but it means you're relying more heavily on the specific pharmacy's quality control and your prescriber's judgment than you would with an approved generic.

How do costs compare across enclomiphene alternatives?

Cost is one of the more concrete ways to compare these options, even though exact prices vary by pharmacy, region, and insurance status (most of this category isn't covered by insurance since it's off-label or compounded). Clomiphene citrate is usually the cheapest, often $20 to $60 a month, because it's a long-generic approved drug available at any standard pharmacy. Enclomiphene typically runs $60 to $150 a month through a compounding pharmacy, reflecting the extra step of custom formulation. Testosterone therapy spans a wide range, cheap generic injectable cypionate can be $30 to $50 a month, while brand gels and pellet implants push well past $150 to $200+. hCG is usually the most expensive non-TRT option, often $150 to $400 a month depending on dose and injection frequency, since it's an injectable peptide hormone rather than an oral tablet. If your budget is the deciding factor and you don't have a specific reason to avoid clomiphene's isomer mix, clomiphene is worth asking your doctor about directly. If you've tried clomiphene and had side effects you didn't like, that's the more common reason people move to enclomiphene despite the higher price, not because enclomiphene has stronger proven outcomes overall.

Can you combine enclomiphene with another therapy instead of switching?

Yes, this is common in practice, though it adds cost and monitoring complexity. The most frequent combination is TRT plus low-dose hCG, used specifically to blunt the testicular shrinkage and fertility suppression that TRT alone causes, since hCG keeps the testes stimulated even while exogenous testosterone silences the pituitary's own signal ^[7]. Some clinicians also pair a SERM with hCG for men actively trying to conceive who have suboptimal semen parameters, on the logic that the SERM handles pituitary signaling while hCG adds direct testicular stimulation. This is a more involved protocol, more monitoring, more injections, more cost, and the evidence for the combination's added benefit over either agent alone is limited to small studies and clinical experience rather than large trials. What you shouldn't do is combine enclomiphene and TRT expecting the enclomiphene to "protect" fertility while on testosterone; once exogenous testosterone is in your system, the suppression pathway is already running, and an oral SERM is not going to reverse it. If preserving fertility while getting testosterone benefits is genuinely your goal, the more evidence-aligned path is a SERM or hCG-based protocol instead of TRT, not on top of it. For a broader look at what results actually look like on enclomiphene alone, see the enclomiphene results timeline and enclomiphene success rate.

Which alternative should you actually choose?

There's no single right answer, it depends on what you're optimizing for. If fertility isn't a concern and you want the most studied, FDA-approved path, TRT (possibly with hCG add-on) is the conventional route your endocrinologist will likely default to. If you want to preserve fertility and don't mind an off-label approved drug, clomiphene is the cheapest, most accessible option with a long track record, even though the zuclomiphene component carries more side-effect baggage for some men. If you've had clomiphene side effects, or want to start with the isomer that's theoretically cleaner, enclomiphene through a compounding pharmacy is the next step up in cost with a smaller but relevant evidence base ^[6]. What I wouldn't reach for first: aromatase inhibitors as a standalone testosterone strategy, or tamoxifen/raloxifene outside of a specialist's specific recommendation, since the male-hypogonadism data for both is thin compared to clomiphene and enclomiphene. The research on enclomiphene specifically is still building, and "preserves fertility better than TRT" is a mechanism-supported claim with some direct human data behind it, not a guarantee for every man. If you go the enclomiphene route, doing it through a provider-reviewed process and a legitimate compounding pharmacy matters more than chasing the lowest price online. Enclomiphene Direct connects patients with providers who review candidacy and prescribe through a compounding pharmacy partner, rather than shipping product with no clinical oversight, which is worth knowing given how unregulated a lot of the online supply chain is. Before committing, it's worth reading real patient experiences at enclomiphene reviews and enclomiphene before and after to calibrate expectations, and weighing the tradeoffs at is enclomiphene worth it.

Frequently asked questions

What is the closest alternative to enclomiphene?

Clomiphene citrate is the closest alternative, since enclomiphene is actually one of the two isomers that make up clomiphene. Clomiphene is FDA-approved (for female infertility, used off-label in men), cheaper, and widely available, but contains zuclomiphene too, which has a much longer half-life and is more linked to estrogenic side effects in some men.

Is there an FDA-approved alternative to enclomiphene?

Testosterone therapy is the main FDA-approved option for low testosterone in men. Clomiphene, tamoxifen, and raloxifene are FDA-approved drugs but not for this indication; they're used off-label. Enclomiphene itself is not FDA-approved for any use; the Androxal development program was discontinued before approval.

Does clomiphene preserve fertility as well as enclomiphene?

Both work upstream at the hypothalamus and generally preserve or support spermatogenesis, unlike TRT. Head-to-head human trials directly comparing fertility outcomes between clomiphene and enclomiphene are limited, so claims that one preserves fertility "better" than the other outrun the current evidence.

Why isn't enclomiphene FDA-approved?

Repros Therapeutics developed enclomiphene as Androxal and ran Phase 3 trials for secondary hypogonadism, but the drug never received FDA approval and the program was discontinued. What's sold today is produced by compounding pharmacies under an individual prescription, not as an approved manufactured drug.

Can you take enclomiphene and TRT together?

Combining them doesn't protect fertility, since exogenous testosterone in TRT suppresses the pituitary signal regardless of the SERM. If fertility preservation is the goal, choose a SERM or hCG-based protocol instead of TRT rather than adding enclomiphene on top of testosterone therapy.

Is hCG better than enclomiphene for fertility?

hCG directly stimulates the testes and can support fertility, especially combined with a SERM, but it doesn't fix pituitary-level signaling problems the way enclomiphene or clomiphene can. It's also injectable and typically more expensive, often $150 to $400 a month versus $60 to $150 for enclomiphene.

What are the side effects of enclomiphene alternatives compared to enclomiphene?

TRT can cause acne, polycythemia, and fertility suppression. Clomiphene shares enclomiphene's side effect profile plus more mood and visual effects tied to zuclomiphene. hCG can cause injection site reactions and gynecomastia risk. Aromatase inhibitors risk low estrogen side effects like joint pain and bone density loss.

Which is cheaper, clomiphene or enclomiphene?

Clomiphene is generally cheaper, often $20 to $60 a month, because it's a long-available generic drug. Enclomiphene typically costs $60 to $150 a month since it requires a compounding pharmacy to isolate the single isomer, which adds preparation cost.

Do SERMs like tamoxifen work as well as enclomiphene for raising testosterone?

Tamoxifen can raise LH and testosterone through the same estrogen-blocking mechanism, but it's approved for breast cancer, not male hypogonadism, and has far less male-specific dosing and outcomes data than clomiphene or enclomiphene. It's a reasonable specialist-directed option, not a well-established first-line alternative.

Does anastrozole raise testosterone as an alternative to enclomiphene?

Anastrozole may modestly raise testosterone by blocking its conversion to estrogen, but it isn't FDA-approved for this use, evidence in men with low-normal testosterone is weak, and pushing estrogen too low can hurt bone density and lipid profiles. It's not considered a mainstream substitute for enclomiphene or clomiphene.

What happens to fertility if you switch from TRT to enclomiphene?

Sperm production can recover after stopping TRT and starting a SERM like enclomiphene, but recovery timelines vary by individual, duration of prior TRT use, and baseline testicular function; some men take many months. There's no guaranteed timeline, and a semen analysis before and during the switch is the only way to actually track it.

Is enclomiphene safer than testosterone therapy?

"Safer" depends on what you're measuring. TRT has a larger, FDA-reviewed safety dataset and more predictable results, but suppresses fertility. Enclomiphene has a smaller evidence base and no FDA approval for any use, but preserves fertility in available studies. Neither is unambiguously "safer" across every outcome that matters to you.

Sources

1. Endocrine Society, Testosterone Therapy in Men With Hypogonadism Clinical Practice Guideline: Exogenous testosterone therapy suppresses spermatogenesis via HPT axis suppression
2. ClinicalTrials.gov, Androxal (enclomiphene citrate) Phase 3 program record: Enclomiphene (Androxal) underwent Phase 3 trials for secondary hypogonadism but was not FDA-approved
3. World Health Organization Task Force, contraceptive efficacy of testosterone-induced azoospermia and oligozoospermia in normal men, Fertility and Sterility: Injectable testosterone regimens suppress sperm concentration to near-zero in most men, supporting its contraceptive potential
4. FDA, Clomiphene Citrate label (Clomid): Clomiphene citrate is FDA-approved for female infertility and is a mixture of enclomiphene and zuclomiphene isomers
5. Kim et al., Clomiphene citrate and testosterone recovery, Translational Andrology and Urology (NCBI): Zuclomiphene has a much longer half-life than enclomiphene and is more associated with estrogenic side effects
6. Kim et al., Enclomiphene citrate pharmacokinetics/endocrine effects study, Journal of Sexual Medicine (PMC): Enclomiphene increased LH, FSH, and total testosterone without suppressing sperm parameters in short-term study
7. FDA, Pregnyl (hCG) prescribing information: hCG is FDA-approved for hypogonadotropic hypogonadism and works by mimicking LH at the testes
8. FDA, Tamoxifen citrate prescribing information: Tamoxifen is FDA-approved for breast cancer, not male hypogonadism, and its testosterone-raising use in men is off-label
9. FDA, Raloxifene (Evista) prescribing information: Raloxifene is FDA-approved for osteoporosis and breast cancer risk reduction, not for male hypogonadism
10. Finkelstein et al., Gonadal steroids and body composition/estrogen role in men, New England Journal of Medicine: Estrogen plays an independent role in male bone health and lipid regulation, relevant to risks of aromatase inhibitor use
11. FDA, Federal Food, Drug, and Cosmetic Act Section 503A compounding provisions: Compounded drugs prepared under section 503A are exempt from standard FDA new-drug approval requirements
12. FDA, Compounding and the FDA: Questions and Answers: FDA states that compounded drugs are not FDA-approved and are not evaluated for safety and effectiveness before marketing